SCHEMBL4962193

SCHEMBL4962193

CCN(C)Cc1cn(Cc2ccc(F)cc2)c2cnc3c(c12)CCN(O)C3=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 1/20 0.36
▸ P2RX7 Q99572 2/20 0.35
▸ MEN1 O00255 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ MAPT P10636 1/20 0.33
▸ KCNH2 Q12809 3/20 0.33
▸ REN P00797 1/20 0.33
▸ CACNB4 O00305 1/20 0.32
▸ CACNA1A O00555 1/20 0.32
▸ CACNA1G O43497 1/20 0.32
▸ CACNG3 O60359 1/20 0.32
▸ CACNA1F O60840 1/20 0.32
▸ CACNA1H O95180 1/20 0.32
▸ CACNB3 P54284 1/20 0.32
▸ CACNA2D1 P54289 1/20 0.32
▸ CACNG7 P62955 1/20 0.32
▸ CACNA1B Q00975 1/20 0.32
▸ CACNA1D Q01668 1/20 0.32
▸ CACNB1 Q02641 1/20 0.32
▸ CACNG1 Q06432 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4964833 0.92 HDAC1 (0.35) PKMP2RX7MEN1KMT2AMAPT
SCHEMBL4962762 0.91 P2RX7 (0.33) PKMP2RX7MEN1KMT2AMAPT
SCHEMBL4966274 0.91 P2RX7 (0.33) PKMP2RX7MEN1KMT2AMAPT
SCHEMBL4962815 0.91 LMNA (0.33) PKMP2RX7MEN1KMT2AMAPT
SCHEMBL4965064 0.90 REN (0.34) PKMP2RX7MEN1KMT2AKCNH2
SCHEMBL4962825 0.89 ALDH1A1 (0.36) PKMP2RX7MEN1KMT2AMAPT
SCHEMBL5419724 0.89 KDM4E (0.43) PKMP2RX7MEN1KMT2AMAPT
SCHEMBL14541908 0.87 REN (0.34) PKMMEN1KMT2AMAPTKCNH2
SCHEMBL4965046 0.87 HTR6 (0.37) PKMMEN1KMT2AMAPTCACNB4
SCHEMBL4963385 0.86 MEN1 (0.36) PKMMEN1KMT2AMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1934220-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME Pfizer Products Incorporated (US) 2008-06-25 — — EP disclosed
US-20070099915-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER INC. 2007-05-03 — — US disclosed
US-20070099915-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER INC. 2007-05-03 — — US disclosed
US-20070099915-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER INC. 2007-05-03 — — US disclosed
WO-2007042883-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER PRODUCTS INC. (US) 2007-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099915-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME IMPDH1, INTS9, TYMP PKM 1971/4885P2RX7 4595/4885MEN1 4787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback